Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

The FDA Approves scPharmaceuticals' Supplemental New Drug Application Seeking To Expand The Furoscix Indication For Heart Failure Patients. At Approval, Furoscix Was Only Indicated For The Treatment Of Congestion Due To Fluid Overload In Adult Patients With New York Heart Association Class II And Class III Chronic Heart Failure

Author: Benzinga Newsdesk | August 12, 2024 06:06am

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class
Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients.

Posted In: SCPH